Jason Prabel

Jason Prabel has over 25 years of work experience in the pharmaceutical industry. Jason currently holds the position of Vice President of CMC R&D at Liquidia Corporation since June 2021. Prior to this, they served as the Executive Director of Analytical R&D at Liquidia Corporation from January 2018 to June 2021. In this role, they led the Analytical R&D group supporting the development of proprietary engineered particle technology for drug product formulations.

Before joining Liquidia Corporation, Jason worked at Eisai Inc. for nearly 17 years. Jason held various positions including Principal Scientist for Formulation & Drug Delivery Technology and Principal Scientist for Analytical Development in the Global Formulation Research department. During their time at Eisai, they focused on the development of parenteral formulations for small molecule candidates from pre-clinical to Phase 3 clinical development. Jason also contributed to liposome delivery, phosphate ester pro-drugs, solubility strategies, injectable formulation, and scale-up design.

Earlier in their career, Jason worked at Magellan Laboratories as a Chemist and Group Leader from July 1994 to October 1998, and at Bioanalytika Laboratories, Inc. as an Analytical Chemist from May 1993 to July 1994.

Throughout their career, Jason has gained extensive expertise in CMC and Analytical strategy, inhalation drug development, stability testing, test method design, impurity evaluations, extractable/leachable assessments, and regulatory submissions.

Jason Prabel has a Bachelor of Science degree in Chemistry from North Carolina State University.